Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension

Hsao Hsun Hsu, Jin Shing Chen, Robert J. Chen, Wen Je Ko, Shuenn Wen Kuo, En Ting Wu, Mei Hwan Wu, Jou Kou Wang, Yung Chie Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study design: We report on the long-term outcome and effects of bosentan treatment in Taiwanese patients with advanced (functional class III or IV) idiopathic pulmonary arterial hypertension (IPAH). Materials and methods: IPAH patients on stable bosentan therapy for more than 12 months and regularly monitored were eligible for this prospective uncontrolled study. Patients were evaluated for several clinical parameters, both measured at the time of initiation of bosentan therapy and after 12 months on therapy: New York Heart Association functional class (NYHA FC), change in 6-min walk distance (6MWD), right ventricle ejection fraction (RVEF), cardiothoracic ratio (CTR), and pulmonary functional status. Results: Twelve of 15 patients met eligibility requirements and were enrolled. Their mean age was 37.6±12.9 years and 92% were female. Six (50%) patients were in NYHA FC IV and the others were in NYHA FC III at baseline. Three (25%) patients were chronic hepatitis C virus (HCV) carriers, with normal liver function. After 12 months of bosentan treatment, 6-MWD, RVEF, and pulmonary function all increased significantly. CTR and NYHA FC both decreased significantly. Oral bosentan was well tolerated and there was no episode of liver dysfunction that required adjustment of the bosentan dosage or discontinuance of therapy. Conclusion: Long-term treatment with oral bosentan appears to have beneficial effects on functional status, exercise capacity, right heart function, and pulmonary function in Taiwanese patients with advanced IPAH, regardless of whether or not they presented with chronic HCV infection.

Original languageEnglish
Pages (from-to)1556-1562
Number of pages7
JournalRespiratory Medicine
Volume101
Issue number7
DOIs
Publication statusPublished - Jul 1 2007
Externally publishedYes

Fingerprint

Chronic Hepatitis C
Hepacivirus
Lung
Therapeutics
Heart Ventricles
Virus Diseases
Familial Primary Pulmonary Hypertension
bosentan
Liver Diseases
Prospective Studies
Exercise
Liver

Keywords

  • Bosentan
  • Endothelin receptor antagonist
  • Idiopathic pulmonary arterial hypertension

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. / Hsu, Hsao Hsun; Chen, Jin Shing; Chen, Robert J.; Ko, Wen Je; Kuo, Shuenn Wen; Wu, En Ting; Wu, Mei Hwan; Wang, Jou Kou; Lee, Yung Chie.

In: Respiratory Medicine, Vol. 101, No. 7, 01.07.2007, p. 1556-1562.

Research output: Contribution to journalArticle

Hsu, Hsao Hsun ; Chen, Jin Shing ; Chen, Robert J. ; Ko, Wen Je ; Kuo, Shuenn Wen ; Wu, En Ting ; Wu, Mei Hwan ; Wang, Jou Kou ; Lee, Yung Chie. / Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension. In: Respiratory Medicine. 2007 ; Vol. 101, No. 7. pp. 1556-1562.
@article{e8108326957f4bf3b4b98953675f60c5,
title = "Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension",
abstract = "Study design: We report on the long-term outcome and effects of bosentan treatment in Taiwanese patients with advanced (functional class III or IV) idiopathic pulmonary arterial hypertension (IPAH). Materials and methods: IPAH patients on stable bosentan therapy for more than 12 months and regularly monitored were eligible for this prospective uncontrolled study. Patients were evaluated for several clinical parameters, both measured at the time of initiation of bosentan therapy and after 12 months on therapy: New York Heart Association functional class (NYHA FC), change in 6-min walk distance (6MWD), right ventricle ejection fraction (RVEF), cardiothoracic ratio (CTR), and pulmonary functional status. Results: Twelve of 15 patients met eligibility requirements and were enrolled. Their mean age was 37.6±12.9 years and 92{\%} were female. Six (50{\%}) patients were in NYHA FC IV and the others were in NYHA FC III at baseline. Three (25{\%}) patients were chronic hepatitis C virus (HCV) carriers, with normal liver function. After 12 months of bosentan treatment, 6-MWD, RVEF, and pulmonary function all increased significantly. CTR and NYHA FC both decreased significantly. Oral bosentan was well tolerated and there was no episode of liver dysfunction that required adjustment of the bosentan dosage or discontinuance of therapy. Conclusion: Long-term treatment with oral bosentan appears to have beneficial effects on functional status, exercise capacity, right heart function, and pulmonary function in Taiwanese patients with advanced IPAH, regardless of whether or not they presented with chronic HCV infection.",
keywords = "Bosentan, Endothelin receptor antagonist, Idiopathic pulmonary arterial hypertension",
author = "Hsu, {Hsao Hsun} and Chen, {Jin Shing} and Chen, {Robert J.} and Ko, {Wen Je} and Kuo, {Shuenn Wen} and Wu, {En Ting} and Wu, {Mei Hwan} and Wang, {Jou Kou} and Lee, {Yung Chie}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.rmed.2006.12.007",
language = "English",
volume = "101",
pages = "1556--1562",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension

AU - Hsu, Hsao Hsun

AU - Chen, Jin Shing

AU - Chen, Robert J.

AU - Ko, Wen Je

AU - Kuo, Shuenn Wen

AU - Wu, En Ting

AU - Wu, Mei Hwan

AU - Wang, Jou Kou

AU - Lee, Yung Chie

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Study design: We report on the long-term outcome and effects of bosentan treatment in Taiwanese patients with advanced (functional class III or IV) idiopathic pulmonary arterial hypertension (IPAH). Materials and methods: IPAH patients on stable bosentan therapy for more than 12 months and regularly monitored were eligible for this prospective uncontrolled study. Patients were evaluated for several clinical parameters, both measured at the time of initiation of bosentan therapy and after 12 months on therapy: New York Heart Association functional class (NYHA FC), change in 6-min walk distance (6MWD), right ventricle ejection fraction (RVEF), cardiothoracic ratio (CTR), and pulmonary functional status. Results: Twelve of 15 patients met eligibility requirements and were enrolled. Their mean age was 37.6±12.9 years and 92% were female. Six (50%) patients were in NYHA FC IV and the others were in NYHA FC III at baseline. Three (25%) patients were chronic hepatitis C virus (HCV) carriers, with normal liver function. After 12 months of bosentan treatment, 6-MWD, RVEF, and pulmonary function all increased significantly. CTR and NYHA FC both decreased significantly. Oral bosentan was well tolerated and there was no episode of liver dysfunction that required adjustment of the bosentan dosage or discontinuance of therapy. Conclusion: Long-term treatment with oral bosentan appears to have beneficial effects on functional status, exercise capacity, right heart function, and pulmonary function in Taiwanese patients with advanced IPAH, regardless of whether or not they presented with chronic HCV infection.

AB - Study design: We report on the long-term outcome and effects of bosentan treatment in Taiwanese patients with advanced (functional class III or IV) idiopathic pulmonary arterial hypertension (IPAH). Materials and methods: IPAH patients on stable bosentan therapy for more than 12 months and regularly monitored were eligible for this prospective uncontrolled study. Patients were evaluated for several clinical parameters, both measured at the time of initiation of bosentan therapy and after 12 months on therapy: New York Heart Association functional class (NYHA FC), change in 6-min walk distance (6MWD), right ventricle ejection fraction (RVEF), cardiothoracic ratio (CTR), and pulmonary functional status. Results: Twelve of 15 patients met eligibility requirements and were enrolled. Their mean age was 37.6±12.9 years and 92% were female. Six (50%) patients were in NYHA FC IV and the others were in NYHA FC III at baseline. Three (25%) patients were chronic hepatitis C virus (HCV) carriers, with normal liver function. After 12 months of bosentan treatment, 6-MWD, RVEF, and pulmonary function all increased significantly. CTR and NYHA FC both decreased significantly. Oral bosentan was well tolerated and there was no episode of liver dysfunction that required adjustment of the bosentan dosage or discontinuance of therapy. Conclusion: Long-term treatment with oral bosentan appears to have beneficial effects on functional status, exercise capacity, right heart function, and pulmonary function in Taiwanese patients with advanced IPAH, regardless of whether or not they presented with chronic HCV infection.

KW - Bosentan

KW - Endothelin receptor antagonist

KW - Idiopathic pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=34249731590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249731590&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2006.12.007

DO - 10.1016/j.rmed.2006.12.007

M3 - Article

C2 - 17223329

AN - SCOPUS:34249731590

VL - 101

SP - 1556

EP - 1562

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 7

ER -